deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT02258607

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

A Phase 1b With Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Sponsor: Sierra Oncology LLC - a GSK company

Conditions Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
Interventions Momelotinib (MMB) Trametinib
Updated 9 times since 2017 Last updated: Jan 30, 2019 Started: Mar 11, 2015 Primary completion: Jul 19, 2016 Completion: Feb 27, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Sierra Oncology LLC - a GSK company

See all terminations from Sierra Oncology LLC - a GSK company

This PHASE1 trial investigates Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Sierra Oncology LLC - a GSK company leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshotActive Not Recruiting~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshotTerminated~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotTerminated~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2023 · 30 months · monthly snapshotTerminated~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2023 [monthly]

    Terminated PHASE1

  5. Mar 2019 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 4 earlier versions

  1. Jun 2018 — Mar 2019 [monthly]

    Terminated PHASE1

  2. Apr 2017 — Jun 2018 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  3. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sierra Oncology LLC - a GSK company
Data source: Sierra Oncology LLC - a GSK company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations